BTEE:LSE:LSE-iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) (USD)

ETF | Others |

Last Closing

USD 7.0815

Change

+0.04 (+0.58)%

Market Cap

N/A

Volume

906.00

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-31 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
0R1O:LSE Amazon.com Inc.

N/A

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

N/A

USD 618.20B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

N/A

USD 544.83B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

N/A

USD 544.83B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
0QZK:LSE Coca-Cola Co.

N/A

USD 266.08B
0QZO:LSE 0QZO

N/A

USD 258.54B
PRJU:LSE Amundi Index Solutions - Amund..

N/A

USD 209.75B
0QZ3:LSE Qualcomm Inc.

N/A

USD 202.26B
0R24:LSE Intel Corp.

N/A

USD 196.14B

ETFs Containing BTEE:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.94% 73% C 68% D+
Dividend Return 0.27% 39% F 67% D+
Total Return 11.22% 74% C 69% C-
Trailing 12 Months  
Capital Gain 20.06% 80% B- 75% C
Dividend Return 0.30% 38% F 66% D+
Total Return 20.35% 79% B- 75% C
Trailing 5 Years  
Capital Gain 48.31% 66% D+ 72% C
Dividend Return 0.97% 25% F 24% F
Total Return 49.28% 64% D 70% C-
Average Annual (5 Year Horizon)  
Capital Gain 5.45% 55% F 60% D-
Dividend Return 5.57% 55% F 59% D-
Total Return N/A 96% N/A 96% N/A
Risk Return Profile  
Volatility (Standard Deviation) 19.05% 36% F 51% F
Risk Adjusted Return 29.23% 52% F 63% D
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.